Research programme: cardiovascular and metabolic disorder therapies - AstraZeneca/Karolinska Institute
Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator AstraZeneca; Karolinska Institute
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders; Metabolic disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cardiovascular-disorders in Sweden
- 16 Jul 2016 No recent reports of development identified for research development in Metabolic-disorders in Sweden
- 21 Mar 2013 Early research in Cardiovascular disorders in Sweden (unspecified route)